These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 3219995)

  • 1. Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.
    Obana Y; Nishino T
    Drugs Exp Clin Res; 1988; 14(5):327-31. PubMed ID: 3219995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
    Obana Y; Nishino T
    Drugs Exp Clin Res; 1989; 15(2):53-8. PubMed ID: 2661182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
    Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A
    Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
    Spivey IM
    Clin Pharm; 1993 Jun; 12(6):452-8. PubMed ID: 8403817
    [No Abstract]   [Full Text] [Related]  

  • 6. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
    Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tavanik effectiveness and safety in the treatment of urinary tract infection complications].
    Loran OB; Pushkar' DIu; Rasner PI
    Klin Med (Mosk); 2001; 79(12):35-8. PubMed ID: 11840809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of the new quinolones in lower respiratory infections.
    Davies BI; Maesen FP
    Chemioterapia; 1987 Jun; 6(2 Suppl):447-8. PubMed ID: 3509469
    [No Abstract]   [Full Text] [Related]  

  • 9. Quinolones for short-term treatment of uncomplicated urinary tract infection.
    Kadiri S; Ajayi SO; Toki RA
    East Afr Med J; 1999 Oct; 76(10):587-9. PubMed ID: 10734512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
    Ozaki M; Matsuda M; Tomii Y; Kimura K; Segawa J; Kitano M; Kise M; Shibata K; Otsuki M; Nishino T
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2496-9. PubMed ID: 1667252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Maxaquin and ciprofloxacin in the treatment of complicated and recurrent urinary infections in adults].
    Savitskaia KI; Trapeznikova MF; Nekhorosheva AG; Solodilova OE; Nasonov VN; Dutov VV; Kalinin VN; Shanina AG; Rusanova EV
    Klin Med (Mosk); 1994; 72(2):38-42. PubMed ID: 8015241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of temafloxacin against respiratory pathogens.
    Swanson RN; Hardy DJ; Chu DT; Shipkowitz NL; Clement JJ
    Antimicrob Agents Chemother; 1991 Mar; 35(3):423-9. PubMed ID: 2039192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fluoroquinolones after ciprofloxacin and ofloxacin.
    Hooper DC
    Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of quinolones on mice experimental infection by Plasmodium berghei and their possible therapeutic usefulness].
    Amato Neto V; Braz LM; Campos R; Matsubara L; Silva Mde F; Pinto PL
    Rev Hosp Clin Fac Med Sao Paulo; 1993; 48(3):116-8. PubMed ID: 8248700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of quinolones in the treatment of lower respiratory tract infections caused by intracellular organisms, excluding mycobacteria].
    Chidiac C; Senneville E; Mouton Y
    Pathol Biol (Paris); 1992 Jun; 40(6):638-45. PubMed ID: 1408383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD; Lamb HM
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The use of Maxaquin (lomefloxacin hydrochloride) in the treatment of nonspecific inflammatory diseases and in the prevention of surgical interventions in urology].
    Derevianko II; Lopatkin NA; Khodyreva LA; Kondrat'eva EM
    Urol Nefrol (Mosk); 1998; (5):14-8. PubMed ID: 9820038
    [No Abstract]   [Full Text] [Related]  

  • 18. Quinolone therapy of Klebsiella pneumoniae sepsis following irradiation: comparison of pefloxacin, ciprofloxacin, and ofloxacin.
    Brook I; Elliott TB; Ledney GD
    Radiat Res; 1990 May; 122(2):215-7. PubMed ID: 2186431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice.
    Hayashi K; Kadowaki SE; Takei M; Fukuda H
    Antimicrob Agents Chemother; 2006 Feb; 50(2):748-51. PubMed ID: 16436736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Microbiological evaluation of ciprofloxacin efficacy for treatment of urinary tract infections].
    Kalisz J; Denys A; Szczerba W; Rusinek A; Rogowska-Kalisz A
    Med Dosw Mikrobiol; 1996; 48(3-4):169-75. PubMed ID: 9182138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.